Skip to content
lifestyle.social-matic.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
F2G, Ltd.
F2G and Shionogi Report Data from Global Phase 3 OASIS Study Evaluating Investigational Oral Olorofim Versus AmBisome® Followed by Standard of Care in Invasive Aspergillosis in Late-Breaking Oral Presentation at IDWeek 2026
October 21, 2026
F2G Announces Posters Accepted for Presentation at Upcoming Medical Meetings
September 1, 2026
F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive Aspergillosis
June 18, 2026